{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:48:54Z","timestamp":1790455734436,"version":"4.1.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>HLA-E presenting the HLA-G leader peptide VMAPRTLFL (HLA-E[pHLA-G]) on tumor cells plays a crucial role in suppressing natural killer (NK) and cytotoxic CD8+ T cells through NKG2A interaction. While blocking HLA-E:NKG2A is a promising immune checkpoint (IC) approach in cancer therapy, toxicity remains a major clinical concern. We developed a novel IC inhibitor that selectively prevents HLA-E:NKG2A interaction, a monoclonal antibody that selectively targets the HLA-E[pHLA-G] complex, distinguishing cancerous from noncancerous cells. In clinical bone marrow samples from patients with multiple myeloma (MM), 4D7 specifically recognized tumor-associated HLA-E\u2013peptide complexes. Using NK cells from healthy donors, 4D7 effectively blocked the HLA-E:NKG2A interaction, and enhanced NKG2A-positive NK cell activity in autologous MM cell cocultures. Importantly, 4D7 did not inhibit NKG2C-positive NK cells, preserving their activity, even though NKG2C also interacts with HLA-E. In MM-bearing mice treated with human NK cells, 4D7 significantly reduced tumor growth. This targeted approach activates NK cells only against tumor cells presenting HLA-E\u2013peptide complexes, potentially minimizing toxicity compared with current NKG2A inhibitors. The development of 4D7 highlights a promising advancement in immunotherapy for hematologic malignancies, offering improved outcomes for patients with MM, and a foundation for broader application across cancer types.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016276","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T20:58:03Z","timestamp":1753390683000},"page":"5436-5448","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["HLA-E[pHLA-G] complex\u2013specific monoclonal antibody enhancing NK activity in multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"given":"Muhammad Abu","family":"Ahmad","sequence":"first","affiliation":[{"name":"1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Radinsky","sequence":"additional","affiliation":[{"name":"1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7740-0473","authenticated-orcid":false,"given":"Bar","family":"Kaufman","sequence":"additional","affiliation":[{"name":"1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0665-9370","authenticated-orcid":false,"given":"Kamran","family":"Waidha","sequence":"additional","affiliation":[{"name":"1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Gharra","sequence":"additional","affiliation":[{"name":"1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Dim","sequence":"additional","affiliation":[{"name":"1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh Babu","family":"Manikandan","sequence":"additional","affiliation":[{"name":"1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Ofir","sequence":"additional","affiliation":[{"name":"1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"2Clinical Cooperation Unit, Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany"},{"name":"3Department of Medical Oncology, Heidelberg University Clinics, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6067-9591","authenticated-orcid":false,"given":"Marten","family":"Meyer","sequence":"additional","affiliation":[{"name":"2Clinical Cooperation Unit, Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany"},{"name":"3Department of Medical Oncology, Heidelberg University Clinics, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3634-9098","authenticated-orcid":false,"given":"Moshe","family":"Elkabets","sequence":"additional","affiliation":[{"name":"1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-7326","authenticated-orcid":false,"given":"Kerry S.","family":"Campbell","sequence":"additional","affiliation":[{"name":"4Blood Cell Development and Host Defense Program, Research Institute at Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6228-9135","authenticated-orcid":false,"given":"Miri","family":"Zektser","sequence":"additional","affiliation":[{"name":"5Internal Medicine A and Multiple Myeloma Clinic, Soroka University Medical Center and Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-2147","authenticated-orcid":false,"given":"Roi","family":"Gazit","sequence":"additional","affiliation":[{"name":"1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ory","family":"Rouvio","sequence":"additional","affiliation":[{"name":"5Internal Medicine A and Multiple Myeloma Clinic, Soroka University Medical Center and Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Momburg","sequence":"additional","affiliation":[{"name":"2Clinical Cooperation Unit, Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany"},{"name":"3Department of Medical Oncology, Heidelberg University Clinics, Heidelberg, Germany"},{"name":"6Antigen Presentation and T\/NK Cell Activation Group, German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1540-4449","authenticated-orcid":false,"given":"Angel","family":"Porgador","sequence":"additional","affiliation":[{"name":"1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"1","key":"2025111014120541100_bib1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025111014120541100_bib2","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2025111014120541100_bib3","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","article-title":"The NK cell\u2013cancer cycle: advances and new challenges in NK cell\u2013based immunotherapies","volume":"21","author":"Bald","year":"2020","journal-title":"Nat Immunol"},{"key":"2025111014120541100_bib4","doi-asserted-by":"crossref","first-page":"592010","DOI":"10.3389\/fimmu.2020.592010","article-title":"Roles of HLA-G in the maternal-fetal immune microenvironment","volume":"11","author":"Xu","year":"2020","journal-title":"Front Immunol"},{"key":"2025111014120541100_bib5","doi-asserted-by":"crossref","first-page":"976289","DOI":"10.3389\/fimmu.2022.976289","article-title":"Advances in the study of HLA class Ib in maternal-fetal immune tolerance","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"2025111014120541100_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/cmi.2014.105","article-title":"Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: so many targets\u2014but how many arrows in the quiver?","volume":"12","author":"Halenius","year":"2015","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"2025111014120541100_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3324\/haematol.2015.135301","article-title":"Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells","volume":"101","author":"Ruggeri","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"2025111014120541100_bib8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00262-015-1694-4","article-title":"Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A","volume":"64","author":"Sarkar","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2025111014120541100_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/bmt.2008.380","article-title":"HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94\/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT","volume":"43","author":"Nguyen","year":"2009","journal-title":"Bone Marrow Transpl"},{"issue":"6669","key":"2025111014120541100_bib10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"issue":"1","key":"2025111014120541100_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/scbi.1998.0107","article-title":"How do NK cells sense the expression of HLA-G class Ib molecules?","volume":"9","author":"L\u00f3pez-Botet","year":"1999","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"2025111014120541100_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2018.07.069","article-title":"Distinct HLA-E peptide complexes modify antibody-driven effector functions of adaptive NK cells","volume":"24","author":"R\u00f6lle","year":"2018","journal-title":"Cell Rep"},{"issue":"1","key":"2025111014120541100_bib13","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41467-023-40220-1","article-title":"High-throughput characterization of HLA-E-presented CD94\/NKG2x ligands reveals peptides which modulate NK cell activation","volume":"14","author":"Huisman","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"2025111014120541100_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/imm.13515","article-title":"NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E","volume":"166","author":"Battin","year":"2022","journal-title":"Immunology"},{"issue":"1","key":"2025111014120541100_bib15","doi-asserted-by":"crossref","first-page":"e1264562","DOI":"10.1080\/2162402X.2016.1264562","article-title":"High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer","volume":"6","author":"Sun","year":"2016","journal-title":"Oncoimmunology"},{"issue":"5","key":"2025111014120541100_bib16","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI123955","article-title":"Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J Clin Invest"},{"issue":"10","key":"2025111014120541100_bib17","doi-asserted-by":"crossref","first-page":"e1226720","DOI":"10.1080\/2162402X.2016.1226720","article-title":"Therapeutic CD94\/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia","volume":"5","author":"McWilliams","year":"2016","journal-title":"Oncoimmunology"},{"issue":"1","key":"2025111014120541100_bib18","doi-asserted-by":"crossref","first-page":"2081415","DOI":"10.1080\/2162402X.2022.2081415","article-title":"CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma","volume":"11","author":"Bexte","year":"2022","journal-title":"Oncoimmunology"},{"issue":"suppl 1","key":"2025111014120541100_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2018-99-116828","article-title":"Increased HLA-E expression correlates with early relapse in multiple myeloma","volume":"132","author":"Lagana","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2025111014120541100_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"issue":"1","key":"2025111014120541100_bib21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","article-title":"Monalizumab: inhibiting the novel immune checkpoint NKG2A","volume":"7","author":"Van Hall","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025111014120541100_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)80447-1","article-title":"Localization, quantitation, and in situ detection of specific peptide- MHC class I complexes using a monoclonal antibody","volume":"6","author":"Porgador","year":"1997","journal-title":"Immunity"},{"issue":"4","key":"2025111014120541100_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.molimm.2010.09.011","article-title":"Anti-HLA-E mAb 3D12 mimics MEM-E\/02 in binding to HLA-B and HLA-C alleles: web-tools validate the immunogenic epitopes of HLA-E recognized by the antibodies","volume":"48","author":"Ravindranath","year":"2011","journal-title":"Mol Immunol"},{"key":"2025111014120541100_bib24","doi-asserted-by":"publisher","DOI":"10.1101\/2022.05.27.493692","article-title":"Mapping the epitopes of the human leukocyte antigen E antibodies 3D12 and 4D12","author":"Brackenridge","year":"29  2022","journal-title":"bioRxiv"},{"issue":"2","key":"2025111014120541100_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nprot.2016.169","article-title":"The ClusPro web server for protein\u2013protein docking","volume":"12","author":"Kozakov","year":"2017","journal-title":"Nat Protoc"},{"issue":"1","key":"2025111014120541100_bib26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s42003-023-04927-7","article-title":"ImmuneBuilder: deep-learning models for predicting the structures of immune proteins","volume":"6","author":"Abanades","year":"2023","journal-title":"Commun Biol"},{"issue":"1","key":"2025111014120541100_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/eji.200324432","article-title":"The inhibitory NK cell receptor CD94\/NKG2A and the activating receptor CD94\/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues","volume":"34","author":"Wada","year":"2004","journal-title":"Eur J Immunol"},{"issue":"9","key":"2025111014120541100_bib28","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1073\/pnas.95.9.5199","article-title":"HLA-E is a major ligand for the natural killer inhibitory receptor CD94\/NKG2A","volume":"95","author":"Lee","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025111014120541100_bib29","doi-asserted-by":"crossref","first-page":"1329032","DOI":"10.3389\/fimmu.2024.1329032","article-title":"The antibodies 3D12 and 4D12 recognise distinct epitopes and conformations of HLA-E","volume":"15","author":"Brackenridge","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"2025111014120541100_bib30","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4049\/jimmunol.171.3.1369","article-title":"Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94\/NKG2","volume":"171","author":"Miller","year":"2003","journal-title":"J Immunol"},{"issue":"1","key":"2025111014120541100_bib31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/10428194.2018.1474521","article-title":"Clinical significance of HLA-E genotype and surface\/soluble expression levels between healthy individuals and patients with acute leukemia","volume":"60","author":"Xu","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2025111014120541100_bib32","doi-asserted-by":"crossref","first-page":"670673","DOI":"10.3389\/fonc.2021.670673","article-title":"HLA-E binding peptide as a potential therapeutic candidate for high-risk multiple myeloma","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"2025111014120541100_bib33","unstructured":"The Human Protein Atlas\n          . Cell line - HLA-G. Accessed 31 May 2025. https:\/\/www.proteinatlas.org\/ENSG00000204632-HLA-G\/cell+line."},{"issue":"1","key":"2025111014120541100_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2025111014120541100_bib35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-020-00965-4","article-title":"In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma","volume":"13","author":"Omstead","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2025111014120541100_bib36","doi-asserted-by":"crossref","first-page":"868695","DOI":"10.3389\/fphar.2022.868695","article-title":"The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment","volume":"13","author":"Kim","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025111014120541100_bib37","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2025111014120541100_bib38","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.humimm.2015.09.003","article-title":"HLA-E regulates NKG2C+ natural killer cell function through presentation of a restricted peptide repertoire","volume":"76","author":"Lauterbach","year":"2015","journal-title":"Hum Immunol"},{"issue":"21","key":"2025111014120541100_bib39","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/1078-0432.CCR-19-2095","article-title":"The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment","volume":"26","author":"Borst","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025111014120541100_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Sig Transduct Target Ther"},{"issue":"7","key":"2025111014120541100_bib41","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/ijc.28484","article-title":"Gastric cancer progression may involve a shift in HLA-E profile from an intact heterodimer to \u03b22-microglobulin-free monomer","volume":"134","author":"Sasaki","year":"2014","journal-title":"Int J Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5436\/2418363\/blooda_adv-2025-016276-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5436\/2418363\/blooda_adv-2025-016276-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T19:12:20Z","timestamp":1762801940000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/21\/5436\/546351\/HLA-E-pHLA-G-complex-specific-monoclonal-antibody"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":41,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016276","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,11]]},"published":{"date-parts":[[2025,10,29]]}}}